Introduction:
AstraZeneca invests US$300 million to open a state-of-the-art manufcaturing facility in Maryland, USA.
Features:
The Rockville facility aims to enhance its manufacturing capabilities to propel advancements in next-generation cell therapy research and development.
The facility will primarily concentrate on manufacturing essential components for cancer trials and introducing commercial cell therapy platforms.
The initial phase will see the creation of over 150 highly skilled positions, primarily dedicated to manufacturing T-cell therapies for global clinical trials. As the site grows, there is a potential for it to broaden its focus and provide support for additional disease areas.
The Rockville facility is set to become part of a global manufacturing and supply network consisting of nearly 30 sites across 16 countries, all either currently operational or under development.
In the US, manufacturing sites prioritise the production of small molecules and biologics, leveraging cutting-edge pharmaceutical technology and development.
Specifications:
Name AstraZeneca
Type New Construction
Budget US$300 million
